D
Daan Gene Co Ltd
SZSE:002030
Daan Gene Co Ltd
SZSE:002030
Price:
6.06 CNY
1.51%
Market Closed
Updated:
Jun 10, 2024
Section:
Relative Value
The Relative Value of one Daan Gene Co Ltd stock under the Base Case scenario is 2.15 CNY. Compared to the current market price of 6.06 CNY, Daan Gene Co Ltd is Overvalued by 64%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
2.15
CNY
Overvaluation 64%
D
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Daan Gene Co Ltd Competitors
Daan Gene Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
D
|
Daan Gene Co Ltd
SZSE:002030
|
8.5B CNY | 8.2 | -28.8 | -14.6 | -14.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
297.4B USD | 5.5 | 50 | 13.9 | 21.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124B USD | 12.2 | 30.9 | 26 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109.5B USD | 8.4 | 28.4 | 23 | 25.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
139.6B AUD | 6.5 | 37.2 | 22.4 | 27.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.1B USD | 2.9 | 165.2 | 8.4 | 11.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
56.3B USD | 10.9 | -9.4 | -10.6 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.3B USD | 3.4 | 28.5 | 14.5 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 17 | 100 | 50.3 | 84 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
